Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Roukens, Anna H ^a   Soonawala, Darius ^a   Joosten, Simone A ^a   de Visser, Adriëtte W ^a   Jiang, Xiaohong ^a   Dirksen, Kees ^b   de Gruijter, Marjolein ^c   van Dissel, Jaap T ^a   Bredenbeek, Peter J ^a   Visser, Leo G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Municipal Health Center Hollands Midden   (Netherlands)

^c Municipal Health Center Leiden   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS RNA; YELLOW FEVER VACCINE;

ADAPTIVE IMMUNITY; ADULT; AGE; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; COPY NUMBER VARIATION; DRUG FEVER; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALE; MASS IMMUNIZATION; MYALGIA; PROSPECTIVE STUDY; RISK FACTOR; VIREMIA; VIRUS NEUTRALIZATION; YELLOW FEVER; BLOOD; CHEMISTRY; CLINICAL TRIAL; METABOLISM; RISK; SERODIAGNOSIS; TIME; VACCINATION; YELLOW FEVER FLAVIVIRUS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; COHORT STUDIES; HUMANS; NEUTRALIZATION TESTS; RISK; RISK FACTORS; TIME FACTORS; VACCINATION; VIREMIA; YELLOW FEVER; YELLOW FEVER VACCINE; YELLOW FEVER VIRUS; YOUNG ADULT;

EID: 82855177831     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027753     Document Type: Article

References (35)

1. Monath TP, (2008) Yellow fever. In: Plotkin SA, Orenstein WA, Paul A, editors. Vaccines 5th ed Philadelphia Saunders Elsevier.
2. Kengsakul K, Sathirapongsasuti K, Punyagupta S, (2002) Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai 85: 131-134.
3. Veit O, Niedrig M, Chapuis-Taillard C, Cavassini M, Mossdorf E, et al. (2009) Swiss HIV Cohort Study. Immunogenicity and safety of yellow fever vaccination of 102 HIV infected patients. Clin Infect Dis 48: 659-566.
4. Hayes EB, (2007) Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 101: 967-971.
5. Martin M, Tsai TF, Cropp B, Chang GJ, Holmes DA, et al. (2001) Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet 358: 98-104.
6. Chan RC, Penney DJ, Little D, Carter IW, Roberts JA, et al. (2001) Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet 358: 121-122.
7. Vasconcelos PF, Luna EJ, Galler R, Silva LJ, Coimbra TL, et al. (2001) Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 358: 91-97.
8. Zhou Q, Liu DW, Shi Y, Long Y, Li DJ, et al. (2005) Adverse effects of attenuated yellow fever vaccine with multiple organ injury-a case report. Zhonghua Yi Xue Za Zhi 85: 936.
9. Gerasimon G, Lowry K, (2005) Rare case of fatal yellow fever vaccine-associated viscerotropic disease. South Med J 98: 653-656.
10. Doblas A, Domingo C, Bae HG, Bohorquez CL, de Ory F, et al. (2006) Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 36: 156-158.
11. Belsher JL, Gay P, Brinton M, DellaValla J, Ridenour R, et al. (2007) Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 25: 8480-8485.
12. Barwick R, (2004) History of thymoma and yellow fever vaccination. Lancet 364: 936.
13. Lindsey NP, Schroeder BA, Miller ER, Braun MM, Hinckley AF, et al. (2008) Adverse event reports following yellow fever vaccination. Vaccine 26: 6077-6082.
14. Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, et al. (2005) Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events. Vaccine 23: 3256-3263.
15. Massad E, Coutinho FAB, Burattini MN, Lopez LF, Struchiner CJ, (2005) Yellow fever vaccination: how much is enough? Vaccine 23: 3908-3914.
16. Martins RM, Galler R, Freire MS, Camacho LA, de Lourdes S, et al. (2007) Yellow fever vaccination: some thoughts on how much is enough. Vaccine 25: 10-11.
17. MMWR (2010) Yellow Fever Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) 59: RR-7.
18. (2005) Global Advisory Committee on Vaccine Safety, 2-3 December 2004. Wkly Epidemiol Rec 80: 3-7.
19. Pawelec G, (2006) Immunity and ageing in man. Exp Gerontol 41: 1239-1242.
20. National Coordination Centre for Traveller's health (LCR) (2008) National guidelines for vaccination and malaria prophylaxis for travellers Amsterdam LCR.
21. De Madrid AT, Porterfield JS, (1969) A simple micro-culture method for the study of group B arboviruses. Bulletin of the World Health Organization 40: 113-121.
22. Mason RA, Tauraso NM, Spertzel RO, Ginn RK, (1973) Yellow fever vaccine: direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 25: 539-544.
23. Roukens AH, Vossen AC, van Dissel JT, Visser LG, (2009) Reduced intradermal test dose of yellow fever vaccine induces protective immunity in individuals with egg allergy. Vaccine 27: 2408-2409.
24. Lang J, Zuckerman J, Clarke P, Barrett P, Kirkpatrick C, et al. (1999) Comparison of the immunogenicity and safety of two yellow fever vaccines. Am J Trop Med Hyg 60: 1045-1050.
25. Drosten C, Gottig S, Schilling S, Asper M, Panning M, et al. (2002) Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40: 2323-2330.
26. Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, et al. (2005) Yellow fever 17D vaccine safety and immunogenicity in the elderly. Hum Vaccin 1: 207-214.
27. Silva ML, Martins MA, Espírito-Santo LR, Campi-Azevedo AC, Silveira-Lemos D, et al. (2011) Characterization of main cytokine sources from the innate and adaptive immune responses following primary 17DD yellow fever vaccination in adults. Vaccine 29: 583-592.
28. Pulendran B, Miller J, Querec TD, Akondy R, Moseley N, et al. (2008) Case of yellow fever vaccine-associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 198: 500-507.
29. Lim JK, Louie CY, Glaser C, Jean C, Johnson B, et al. (2008) Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 197: 262-265.
30. Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B, (2008) Biology of immune responses to vaccines in elderly persons. Clin Infect Dis 46: 1078-1084.
31. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, et al. (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10: 116-125.
32. Barrett AD, Niedrig M, Teuwen DE, (2008) International laboratory network for yellow fever vaccine-associated adverse events. Vaccine 26: 5441-5442.
33. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG, (2008) Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS ONE 3: e1993.
34. Monath TP, Lee CK, Julander JG, Brown A, Beasley DW, et al. (2010) Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity. Vaccine 28: 3827-3840.
35. Monath TP, Fowler E, Johnson CT, Balser J, Morin MJ, et al. (2011) An inactivated cell cultured yellow fever vaccine. N Engl J Med 364: 1326-33.